Erlotinib Completed Phase 1 Trials for Advanced Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00903734An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
NCT00895362Erlotinib in Combination With Cetuximab